Fig. 3From: Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective studyKaplan-Meier event curve depicting probability of neoplasm development from start of biologic therapy in patients with JIA (n = 295) from the Rheumatology Biologic Registry. Dashed lines represents 95% Confidence IntervalBack to article page